Education
About Us
Working with TipRanks
Follow Us
Castle Biosciences (CSTL)
NASDAQ:CSTL
CSTL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$16.97 - $35.84
Previous CloseN/A
Volume108.23K
Average Volume (3M)404.48K
Market Cap
$618.19M
Enterprise Value$585.47M
Total Cash (Recent Filing)$82.95M
Total Debt (Recent Filing)$25.05M
Price to Earnings (P/E)35.4
Beta0.85
Next Earnings
May 12, 2025EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.61
Shares Outstanding28,514,109
10 Day Avg. Volume440,545
30 Day Avg. Volume404,480
Standard Deviation0.16
R-Squared0.09
Alpha0.00231
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.98
Price to Cash Flow (P/CF)6.60
P/FCF Ratio9.10
Enterprise Value/Market Cap0.95
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.35
Enterprise Value/Ebitda23.35
Forecast
1Y Price Target
$40.00Price Target Upside84.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Castle Biosciences News
PremiumCompany Announcements
Castle Biosciences’ 2024 Earnings: Growth Amid Challenges
PremiumCompany Announcements
Castle Biosciences Reports Strong 2024 Financial Results---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceCastle reported 4Q24 revenues of $86.3M, well ahead of consensus of $80.4M and estimate of $82.3M.
Growth StrategyCastle expects TissueCypher to be a key growth driver in 2025, supported by expansions to the sales force, with significant revenue growth anticipated.
Bears Say
Reimbursement ChallengesNovitas' negative DDx-SCC coverage decision means minimal reimbursement going forward.
---
Ownership Overview
2.80% Insiders
27.73% Mutual Funds
26.21% Other Institutional Investors
29.15% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CSTL FAQ
What was Castle Biosciences’s price range in the past 12 months?
Castle Biosciences lowest stock price was $16.96 and its highest was $35.84 in the past 12 months.
What is Castle Biosciences’s market cap?
Castle Biosciences’s market cap is $618.19M.
When is Castle Biosciences’s upcoming earnings report date?
Castle Biosciences’s upcoming earnings report date is May 12, 2025 which is in 70 days.
How were Castle Biosciences’s earnings last quarter?
Castle Biosciences released its earnings results on Feb 27, 2025. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.047 by $0.273.
Is Castle Biosciences overvalued?
According to Wall Street analysts Castle Biosciences’s price is currently Undervalued.
Does Castle Biosciences pay dividends?
Castle Biosciences does not currently pay dividends.
What is Castle Biosciences’s EPS estimate?
Castle Biosciences’s EPS estimate is -0.16.
How many shares outstanding does Castle Biosciences have?
Castle Biosciences has 28,514,109 shares outstanding.
What happened to Castle Biosciences’s price movement after its last earnings report?
Castle Biosciences reported an EPS of $0.32 in its last earnings report, beating expectations of $0.047. Following the earnings report the stock price went down -14.241%.
Which hedge fund is a major shareholder of Castle Biosciences?
Currently, no hedge funds are holding shares in CSTL
---
Castle Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$40.00 (84.50% Upside)
$40.00 (84.50% Upside)
Blogger Sentiment
Bullish
CSTL Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 92.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 12.0%
Last 30 Days ▼ 12.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-11.11%
12-Months-Change
Fundamentals
Return on Equity
4.31%
Trailing 12-Months
Asset Growth
15.93%
Trailing 12-Months
Company Description
Castle Biosciences
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, which is a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.
---
CSTL Company Deck
---
CSTL Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Castle Biosciences reported strong revenue growth and profitability in 2024, with significant increases in test report volumes and cash reserves. However, the anticipated loss of Medicare coverage for DecisionDx-SCC poses a challenge, along with expected declines in the mental health segment. Despite these challenges, the company shows strong financial health and growth potential.Read More>---
CSTL Stock 12 Month Forecast
Average Price Target
$40.00
▲(84.50% Upside)
Technical Analysis
Best Analysts Covering CSTL
1 Year
1 Year Success Rate
9/18 ratings generated profit
1 Year Average Return
+15.62%
reiterated a buy rating 2 months ago
Copying Sung Ji Nam's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +15.62% per trade.
---